{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:52:08Z","timestamp":1791996728573,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Div"],"DOI":"10.1186\/s13008-026-00192-2","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T17:12:52Z","timestamp":1784481172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NSUN2 regulates PARP9 progression through m5C modification to mediate breast cancer progression"],"prefix":"10.1186","volume":"21","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengqiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yike","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,19]]},"reference":[{"key":"192_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"192_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/14737140.2023.2257393","volume":"23","author":"SA Narod","year":"2023","unstructured":"Narod SA, Dent R. Triple-negative breast cancers. Expert Rev Anticancer Ther. 2023;23:1041\u20133.","journal-title":"Expert Rev Anticancer Ther"},{"key":"192_CR3","doi-asserted-by":"publisher","first-page":"115209","DOI":"10.1016\/j.bcp.2022.115209","volume":"204","author":"AT Jacobs","year":"2022","unstructured":"Jacobs AT, Martinez Castaneda-Cruz D, Rose MM, Connelly L. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochem Pharmacol. 2022;204:115209.","journal-title":"Biochem Pharmacol"},{"key":"192_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","volume":"60","author":"Y Liang","year":"2020","unstructured":"Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14\u201327.","journal-title":"Semin Cancer Biol"},{"key":"192_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2174\/0118744710254730231114181358","volume":"17","author":"K Ayse G\u00fclbin","year":"2024","unstructured":"Ayse G\u00fclbin K, Ihsan K, Ahmet S, Seniz D, Abdullah Tuncay D. Impact of Radiation Therapy on Serum Humanin and MOTS-c Levels in Patients with Lung or Breast Cancer. Curr Radiopharmaceut. 2024;17:229\u201337.","journal-title":"Curr Radiopharmaceut"},{"key":"192_CR6","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.3390\/ijms23126806","volume":"23","author":"M Park","year":"2022","unstructured":"Park M, Kim D, Ko S, Kim A, Mo K, Yoon H. Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. Int J Mol Sci. 2022;23:6806.","journal-title":"Int J Mol Sci"},{"key":"192_CR7","doi-asserted-by":"publisher","first-page":"100101","DOI":"10.1016\/j.lddd.2025.100101","volume":"22","author":"KS Vivekananda","year":"2025","unstructured":"Vivekananda KS. Identification of breast cancer biomarkers through bioinformatics approach. Lett Drug Des Discov. 2025;22:100101.","journal-title":"Lett Drug Des Discov"},{"key":"192_CR8","doi-asserted-by":"publisher","first-page":"1599305","DOI":"10.3389\/fimmu.2025.1599305","volume":"16","author":"X Chen","year":"2025","unstructured":"Chen X, Yuan Y, Zhou F, Huang X, Li L, Pu J, et al. RNA m5C modification: from physiology to pathology and its biological significance. Front Immunol. 2025;16:1599305.","journal-title":"Front Immunol"},{"key":"192_CR9","doi-asserted-by":"publisher","first-page":"e70239","DOI":"10.1002\/ctm2.70239","volume":"15","author":"L Zhang","year":"2025","unstructured":"Zhang L, Li Y, Li L, Yao F, Cai M, Ye D, et al. Detection, molecular function and mechanisms of m5C in cancer. Clin Transl Med. 2025;15:e70239.","journal-title":"Clin Transl Med"},{"key":"192_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12967-022-03427-2","volume":"20","author":"M Li","year":"2022","unstructured":"Li M, Tao Z, Zhao Y, Li L, Zheng J, Li Z, et al. 5-methylcytosine RNA methyltransferases and their potential roles in cancer. J Transl Med. 2022;20:214.","journal-title":"J Transl Med"},{"key":"192_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/genes10020102","volume":"10","author":"KE Bohnsack","year":"2019","unstructured":"Bohnsack KE, Hobartner C, Bohnsack MT. Eukaryotic 5-methylcytosine (m(5)C) RNA Methyltransferases: Mechanisms, Cellular Functions, and Links to Disease. Genes (Basel). 2019;10:102.","journal-title":"Genes (Basel)"},{"key":"192_CR12","doi-asserted-by":"publisher","first-page":"111375","DOI":"10.1016\/j.cellsig.2024.111375","volume":"123","author":"P Li","year":"2024","unstructured":"Li P, Huang D. NSUN2-mediated RNA methylation: Molecular mechanisms and clinical relevance in cancer. Cell Signal. 2024;123:111375.","journal-title":"Cell Signal"},{"key":"192_CR13","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.curpro.2025.100029","volume":"22","author":"L Wang","year":"2025","unstructured":"Wang L, Zhou D, Ou Y. NSUN2\/FOXM1 positive feedback pathway promotes the malignant development of non-small cell lung cancer. Curr Proteom. 2025;22:100029.","journal-title":"Curr Proteom"},{"key":"192_CR14","doi-asserted-by":"publisher","first-page":"e1621","DOI":"10.1002\/ctm2.1621","volume":"14","author":"S Zou","year":"2024","unstructured":"Zou S, Huang Y, Yang Z, Zhang J, Meng M, Zhang Y, et al. NSUN2 promotes colorectal cancer progression by enhancing SKIL mRNA stabilization. Clin Transl Med. 2024;14:e1621.","journal-title":"Clin Transl Med"},{"key":"192_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41419-023-05646-x","volume":"14","author":"M Yang","year":"2023","unstructured":"Yang M, Wei R, Zhang S, Hu S, Liang X, Yang Z, et al. NSUN2 promotes osteosarcoma progression by enhancing the stability of FABP5 mRNA via m(5)C methylation. Cell Death Dis. 2023;14:125.","journal-title":"Cell Death Dis"},{"key":"192_CR16","doi-asserted-by":"publisher","first-page":"217939","DOI":"10.1016\/j.canlet.2025.217939","volume":"631","author":"M Zhang","year":"2025","unstructured":"Zhang M, Tang C, Li S, Jiang X, Li B, Chen Y, et al. NSUN2-mediated m(5)C modification of KDM6B mRNA enhances osteoclast differentiation and promotes breast cancer bone metastasis. Cancer Lett. 2025;631:217939.","journal-title":"Cancer Lett"},{"key":"192_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13058-024-01847-0","volume":"26","author":"X Zhang","year":"2024","unstructured":"Zhang X, An K, Ge X, Sun Y, Wei J, Ren W, et al. NSUN2\/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m(5)C methylation. Breast Cancer Res. 2024;26:94.","journal-title":"Breast Cancer Res"},{"key":"192_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrm3376","volume":"13","author":"BA Gibson","year":"2012","unstructured":"Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13:411\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"192_CR19","doi-asserted-by":"publisher","first-page":"e0316476","DOI":"10.1371\/journal.pone.0316476","volume":"19","author":"Y Li","year":"2024","unstructured":"Li Y, Wang X, Liu X, Li X, Zhang J, Li Y. The dysregulation of PARP9 expression is linked to apoptosis and DNA damage in gastric cancer cells. PLoS ONE. 2024;19:e0316476.","journal-title":"PLoS ONE"},{"key":"192_CR20","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/cns.13380","volume":"26","author":"H Xu","year":"2020","unstructured":"Xu H, Chai S, Wang Y, Wang J, Xiao D, Li J, et al. Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target. CNS Neurosci Ther. 2020;26:804\u201314.","journal-title":"CNS Neurosci Ther"},{"key":"192_CR21","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.5114\/aoms\/161444","volume":"20","author":"T Hong","year":"2024","unstructured":"Hong T, Dong D, Li J, Wang L. PARP9 knockdown confers protection against chemoresistance and immune escape of breast cancer cells by blocking the PI3K\/AKT pathway. Arch Med Sci. 2024;20:1228\u201348.","journal-title":"Arch Med Sci"},{"key":"192_CR22","doi-asserted-by":"publisher","first-page":"1584087","DOI":"10.3389\/fimmu.2025.1584087","volume":"16","author":"Z Kang","year":"2025","unstructured":"Kang Z, Wang J, Liu J, Du L, Liu X. Epigenetic modifications in breast cancer: from immune escape mechanisms to therapeutic target discovery. Front Immunol. 2025;16:1584087.","journal-title":"Front Immunol"},{"key":"192_CR23","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/cells9081758","volume":"9","author":"A Chellamuthu","year":"2020","unstructured":"Chellamuthu A, Gray SG. The RNA Methyltransferase NSUN2 and Its Potential Roles in Cancer. Cells. 2020;9:1758.","journal-title":"Cells"},{"key":"192_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.hbpd.2025.05.001","volume":"24","author":"XY Sun","year":"2025","unstructured":"Sun XY, Yu B, Yu J, Wang YP, Li XB, Sun RR, et al. YBX1 is required for maintaining PD-L1 expression in intrahepatic cholangiocarcinoma by regulating STAT1 stability in an m5C-dependent manner. Hepatobiliary Pancreat Dis Int. 2025;24:643\u201355.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"192_CR25","doi-asserted-by":"publisher","DOI":"10.2174\/0113862073392269250825105059","author":"H Li","year":"2025","unstructured":"Li H, Liang Y, Tang J, Luo H, Wang Y. YBX1 Enhances the Stability of TM4SF1 in an m5C-Dependent Manner to Promote Bladder Cancer Proliferation and Glycolysis. Comb Chem High Throughput Screen. 2025. https:\/\/doi.org\/10.2174\/0113862073392269250825105059.","journal-title":"Comb Chem High Throughput Screen"},{"key":"192_CR26","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s12276-024-01184-4","volume":"56","author":"X Liu","year":"2024","unstructured":"Liu X, Wei Q, Yang C, Zhao H, Xu J, Mobet Y, et al. RNA m(5)C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer. Exp Mol Med. 2024;56:600\u201315.","journal-title":"Exp Mol Med"},{"key":"192_CR27","first-page":"4073","volume":"16","author":"X Tang","year":"2018","unstructured":"Tang X, Zhang H, Long Y, Hua H, Jiang Y, Jing J. PARP9 is overexpressed in human breast cancer and promotes cancer cell migration. Oncol Lett. 2018;16:4073\u20137.","journal-title":"Oncol Lett"},{"key":"192_CR28","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.3390\/cancers13092042","volume":"13","author":"MA Demeny","year":"2021","unstructured":"Demeny MA, Virag L. The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallm Cancers (Basel). 2021;13:2042.","journal-title":"Cell Intrinsic Hallm Cancers (Basel)"},{"key":"192_CR29","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/imm.12665","volume":"149","author":"D Ozkazanc","year":"2016","unstructured":"Ozkazanc D, Yoyen-Ermis D, Tavukcuoglu E, Buyukasik Y, Esendagli G. Functional exhaustion of CD4(+) T cells induced by co-stimulatory signals from myeloid leukaemia cells. Immunology. 2016;149:460\u201371.","journal-title":"Immunology"},{"key":"192_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41419-020-2487-z","volume":"11","author":"L Mei","year":"2020","unstructured":"Mei L, Shen C, Miao R, Wang JZ, Cao MD, Zhang YS, et al. RNA methyltransferase NSUN2 promotes gastric cancer cell proliferation by repressing p57(Kip2) by an m(5)C-dependent manner. Cell Death Dis. 2020;11:270.","journal-title":"Cell Death Dis"},{"key":"192_CR31","doi-asserted-by":"publisher","first-page":"e1273","DOI":"10.1002\/ctm2.1273","volume":"13","author":"S Zuo","year":"2023","unstructured":"Zuo S, Li L, Wen X, Gu X, Zhuang A, Li R, et al. NSUN2-mediated m(5) C RNA methylation dictates retinoblastoma progression through promoting PFAS mRNA stability and expression. Clin Transl Med. 2023;13:e1273.","journal-title":"Clin Transl Med"},{"key":"192_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41419-025-07414-5","volume":"16","author":"Q Qi","year":"2025","unstructured":"Qi Q, Zhong R, Huang Y, Tang Y, Zhang XW, Liu C, et al. The RNA M5C methyltransferase NSUN2 promotes progression of hepatocellular carcinoma by enhancing PKM2-mediated glycolysis. Cell Death Dis. 2025;16:82.","journal-title":"Cell Death Dis"},{"key":"192_CR33","doi-asserted-by":"publisher","first-page":"20751","DOI":"10.18632\/oncotarget.10612","volume":"8","author":"J Yi","year":"2017","unstructured":"Yi J, Gao R, Chen Y, Yang Z, Han P, Zhang H, et al. Overexpression of NSUN2 by DNA hypomethylation is associated with metastatic progression in human breast cancer. Oncotarget. 2017;8:20751\u201365.","journal-title":"Oncotarget"},{"key":"192_CR34","doi-asserted-by":"publisher","first-page":"e18761429263063","DOI":"10.2174\/0118761429263063231204095516","volume":"17","author":"MH Pourhanifeh","year":"2024","unstructured":"Pourhanifeh MH, Farrokhi-Kebria H, Mostanadi P, Farkhondeh T, Samarghandian S. Anticancer Properties of Baicalin against Breast Cancer and other Gynecological Cancers: Therapeutic Opportunities based on Underlying Mechanisms. Curr Mol Pharmacol. 2024;17:e18761429263063.","journal-title":"Curr Mol Pharmacol"},{"key":"192_CR35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2174\/0113892029305656240503045154","volume":"25","author":"MS Hussain","year":"2024","unstructured":"Hussain MS, Agrawal M, Shaikh NK, Saraswat N, Bahl G, Maqbool Bhat M, et al. Beyond the Genome: Deciphering the Role of MALAT1 in Breast Cancer Progression. Curr Genomics. 2024;25:343\u201357.","journal-title":"Curr Genomics"}],"container-title":["Cell Division"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13008-026-00192-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13008-026-00192-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13008-026-00192-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:43:56Z","timestamp":1791996236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13008-026-00192-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["192"],"URL":"https:\/\/doi.org\/10.1186\/s13008-026-00192-2","relation":{},"ISSN":["1747-1028"],"issn-type":[{"value":"1747-1028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,19]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consents were provided by the participants. The study was approved by the Ethics Committee of Xijing Hospital (KY20192014-C-1). All procedures involving human tissues were performed in accordance with the Declaration of Helsinki. The animal study was approved by the Ethics Committee of Xijing Hospital (20240780). Animal care and experimental procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"20"}}